Sponsored: MD Anderson Cancer Center’s ‘Sprint For Life’ 5K Race/Walk
Sprint For Life raises awareness of ovarian cancer in the community and raises important research funds.
Sprint For Life raises awareness of ovarian cancer in the community and raises important research funds.
Tagraxofusp is the first drug for BPDCN, and the first CD123-targeting drug in oncology, to receive FDA approval.
The FDA has granted accelerated approval to lisocabtagene maraleucel for the treatment of select adult patients with relapsed or refractory follicular lymphoma.
Adaptation of transfer learning to relate human single-cell RNA sequencing data to organoid-CAF cocultures facilitates discovery of human pancreatic cancer intercellular interactions and uncovers cross-talk…
Lisocabtagene maraleucel has been granted FDA approval for the treatment of patients with relapsed/refractory follicular lymphoma.
This noninferiority randomized trial compares the effects of a wireless system designed to provide daily feedback on progress in lifestyle change and weight loss vs…
An international genomics study has revealed distinct mutational signatures in kidney cancer that vary across different regions, illuminating the reasons behind global disparities in incidence…
Pertuzumab plus trastuzumab produced antitumor activity and a mild adverse effect profile in patients with pretreated biliary tract cancer with ERBB2/3 alterations.
Supported by an independent educational grant from Servier. Join us for an interactive a nd engaging symposium that takes a deep dive into the latest…
This clinical insights article is derived from recommendations in Palliative Care for Patients with Cancer: ASCO Guideline. This document is based on an ASCO Guideline…
According to results from the ongoing phase 1 TROPION-PanTumor01 trial, datopotamab deruxtecan demonstrated promising efficacy and safety among heavily pretreated patients with advanced or metastatic…